MCF Advisors LLC reduced its holdings in shares of Pfizer (NYSE:PFE) by 15.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,878 shares of the biopharmaceutical company’s stock after selling 2,270 shares during the quarter. MCF Advisors LLC’s holdings in Pfizer were worth $466,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Delphi Private Advisors LLC grew its holdings in shares of Pfizer by 84.3% during the fourth quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 1,600 shares during the last quarter. Americafirst Capital Management LLC purchased a new position in Pfizer during the third quarter worth about $127,000. Oak Point Wealth Management purchased a new position in Pfizer during the fourth quarter worth about $165,000. Cerebellum GP LLC purchased a new position in Pfizer during the fourth quarter worth about $166,000. Finally, Lipe & Dalton boosted its holdings in Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 71.33% of the company’s stock.
In other news, Director W Don Cornwell sold 1,758 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total value of $64,676.82. Following the sale, the director now owns 1,000 shares of the company’s stock, valued at $36,790. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Charles H. Hill sold 42,393 shares of the business’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total transaction of $1,515,973.68. The disclosure for this sale can be found here. In the last three months, insiders sold 248,037 shares of company stock worth $9,064,785. Insiders own 0.06% of the company’s stock.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the company earned $0.47 earnings per share. research analysts anticipate that Pfizer will post 2.96 earnings per share for the current fiscal year.
Several research analysts recently weighed in on PFE shares. SunTrust Banks restated a “hold” rating and set a $40.00 price target (up from $33.00) on shares of Pfizer in a report on Monday, January 29th. Jefferies Group set a $39.00 price target on shares of Pfizer and gave the stock a “hold” rating in a report on Monday, February 26th. Morningstar set a $38.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. BMO Capital Markets set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, March 6th. Finally, Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $37.98 price target on the stock. in a report on Monday, January 15th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $39.20.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.